After months of suspense, two pharmaceutical industry trade groups have agreed to drop a lawsuit against the state of Nevada over a new law that requires drug makers to report a wide array of pricing information about their diabetes medicines.
The move comes just weeks after state officials modified a regulation to allow companies to mark certain pricing data as confidential when they begin complying with the new transparency law, according to court documents.
“The most significant legal flaw in (the law) has been addressed through the regulatory process,” said James Stansel, executive vice president and general counsel at the Pharmaceutical Research and Manufacturers of America which, along with the Biotechnology Innovation Organization, filed the lawsuit last fall on constitutional grounds.
About the Author Reprints
